The conference call may be accessed by dialing 866-783-2140 forparticipants in the U.S. or Canada and 857-350-1599 for internationalcallers (reference passcode 53357519). A telephone replay of theconference call may be accessed through March 23, 2010 by dialing888-286-8010 for callers in the U.S. or Canada and 617-801-6888 forinternational callers (reference passcode 56612031). The conference callalso will be webcast live on ACADIA's website, www.acadia-pharm.com,under the investors section and will be archived there until March 23,2010.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments forcentral nervous system disorders. ACADIA is currently developing aportfolio consisting of four product candidates including pimavanserin,which is being developed for three separate neurological and psychiatricindications in collaboration with Biovail. These indications areParkinson's disease psychosis, which is in Phase III development,adjunctive therapy for schizophrenia, which is in Phase III planning,and Alzheimer's disease psychosis, for which ACADIA is planning toinitiate a Phase II feasibility study. In addition to pimavanserin,ACADIA has a product candidate in Phase II development for chronic painand a product candidate in Phase I development for glaucoma, both incollaboration with Allergan, and a program in IND-track development incollaboration with Meiji Seika Kaisha. All of the product candidates inACADIA's pipeline emanate from discoveries made using its proprietarydrug discovery platform.
ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.
SOURCE: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Vice President and Chief Financial Officer
(858) 558-2871